Paolo Paoletti joins PsiOxus Therapeutics at Chairman

Former President of GSK Oncology adds depth of knowledge of cancer R&D

PsiOxus Therapeutics, a UK-based immuno-oncology company that develops novel therapeutics for serious diseases with a particular focus on cancer, has appointed Paolo Paoletti as Chairman of the Board.

Paoletti was most recently President of GlaxoSmithKline (GSK) Oncology. In this role, he was responsible for R&D, commercial strategy and lifecycle management. Prior to joining GSK, he was Vice President, Clinical Development for Lilly Oncology.

In addition to his role at PsiOxus, Paoletti is also a member of the boards of Genmab, Forma Therapeutics and Nucana BioMed, as well as being the CEO of Kesios Therapeutics.

You may also like